Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 7,078 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer Clear all
Recruiting Phase 2 Interventional

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

NCT07427394
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Camizestrant, Atirmociclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
St Louis, Missouri • East Providence, Rhode Island • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 31, 2026, 9:36 PM EDT
Completed Phase 2 Interventional

Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)

NCT00203372
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab 7.5 and TAC, Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), Bevacizumab 15 and TAC, Placebo 15 and TAC
Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
5
States / cities
Los Angeles, California • Pomona, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 31, 2026, 9:36 PM EDT
Completed Phase 3 Interventional

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

NCT02032277
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Cyclophosphamide, Placebo, Doxorubicin, Paclitaxel, Carboplatin, Veliparib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
61
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 31, 2026, 9:36 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Earlier Breast Cancer Detection Using Automated Whole Breast Ultrasound With Mammography, Including Cost Comparisons

NCT00649337
View directory record Official record
Conditions
Breast Neoplasms, Ultrasonography
Interventions
Comparison of Automated Whole Breast Ultrasound Screening with Blinded Screening Mammography
Procedure
Lead sponsor
SonoCine, Inc.
Industry
Eligibility
35 Years to 90 Years · Female only
Enrollment
4,650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Oct 31, 2026, 9:36 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers Results available

Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening

NCT04877912
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI Abbreviated Scan, Abbreviated MRI Scan
Diagnostic Test
Lead sponsor
University of Chicago
Other
Eligibility
40 Years to 74 Years · Female only
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 31, 2026, 9:36 PM EDT
Not yet recruiting Phase 2 Interventional

De-EscaLaTion of Aromatase Inhibitor Therapy: A Randomized Phase II Study of De-escalated Letrozole in Hormone Receptor-Positive Early Breast Cancer

NCT07866430
View directory record Official record
Conditions
Brest Cancer ER+ and HER2 Negative
Interventions
Letrozole
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 59 Years · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 31, 2026, 9:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer

NCT00054028
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions
suramin, paclitaxel, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 31, 2026, 9:36 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

NCT03606967
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Computed Tomography, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Nab-paclitaxel, Personalized Synthetic Long Peptide Vaccine, Poly ICLC, Sacituzumab Govitecan, Tremelimumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
30
States / cities
Orange, California • Sacramento, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 9:36 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Improving Survivorship Among Minority Cancer Dyads

NCT04685551
View directory record Official record
Conditions
Cancer, Breast Cancer, Colon Cancer, Caregiver Burnout, Lung Cancer
Interventions
Change in knowledge, motivation, skills, and resources
Behavioral
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 31, 2026, 9:36 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

NCT00099437
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
45 Years to 130 Years · Female only
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2026
U.S. locations
14
States / cities
Casa Grande, Arizona • Fountain Valley, California • New Britain, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 31, 2026, 9:36 PM EDT
Completed No phase listed Observational

NBRST: Prospective Neo-adjuvant REGISTRY Trial

NCT01479101
View directory record Official record
Conditions
Breast Cancer
Interventions
MammaPrint 70-gene expression profile, BluePrint 80 gene expression profile
Other
Lead sponsor
Agendia
Industry
Eligibility
18 Years to 90 Years · Female only
Enrollment
1,142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
76
States / cities
Glendale, Arizona • Scottsdale, Arizona • Berkeley, California + 67 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 31, 2026, 9:36 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Acute Exercise Intervention in Breast Cancer Survivors

NCT03779867
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Exercise Intervention, Resting, Biomarker Analysis, Questionnaire Administration
Behavioral · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 31, 2026, 9:36 PM EDT
Completed Phase 1 Interventional

Clinical Trial of Trametes Versicolor in Women With Breast Cancer

NCT00680667
View directory record Official record
Conditions
Breast Cancer
Interventions
Coriolus versicolor extract
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Minneapolis, Minnesota • Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 31, 2026, 9:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Full-Field Digital Mammography With Digital Breast Tomography for Screening Call-Back Rates

NCT01236781
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Screening Tomosynthesis, Diagnostic Tomosynthesis
Device
Lead sponsor
American College of Radiology
Other
Eligibility
25 Years and older · Female only
Enrollment
558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 31, 2026, 9:36 PM EDT
Not listed Not applicable Interventional

Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)

NCT03025139
View directory record Official record
Conditions
Cancer Survivor, Early-Stage Breast Carcinoma, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Educational Intervention, Laboratory Biomarker Analysis, Meditation Therapy, Questionnaire Administration
Other · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Up to 49 Years · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 31, 2026, 9:36 PM EDT
Completed No phase listed Observational

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

NCT00003329
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions
gene mapping
Genetic
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
0 Years to 120 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
32
States / cities
Rancho Mirage, California • Fort Collins, Colorado • Boca Raton, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 31, 2026, 9:36 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Johns Hopkins Breast Cancer Program Longitudinal Repository

NCT01937039
View directory record Official record
Conditions
Breast Cancer, Benign Breast Disease
Interventions
Sample collection
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 31, 2026, 9:36 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

NCT03403712
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
fosnetupitant/ palonosetron, netupitant/palonosetron, dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
36
States / cities
Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 31, 2026, 9:36 PM EDT
Completed Not applicable Interventional

Pain Management Following TRAM Flap for Breast Reconstruction

NCT00500565
View directory record Official record
Conditions
Breast Cancer
Interventions
Saline, Bupivicaine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Oct 31, 2026, 9:36 PM EDT
Terminated Phase 3 Interventional Results available

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

NCT00520975
View directory record Official record
Conditions
Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Bevacizumab, Carboplatin, Paclitaxel, Placebo, Trastuzumab
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
373
States / cities
Jonesboro, Arkansas • Castro Valley, California • Emeryville, California + 236 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 31, 2026, 9:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery

NCT05583981
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Interview
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 31, 2026, 9:36 PM EDT
Not yet recruiting No phase listed Observational

SNAPS Breast Cancer Patient Study Breast Cancer Patients

NCT05370300
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female
Interventions
Blood test
Diagnostic Test
Lead sponsor
Immunis.AI
Industry
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 31, 2026, 9:36 PM EDT
Completed Not applicable Interventional

Evaluation of Intraoperative Usage of Sentinella in Detecting Sentinel Lymph Nodes

NCT02416336
View directory record Official record
Conditions
Melanoma, Head and Neck Cancer, Breast Cancer
Interventions
Sentinella Intraoperative imaging protocol
Device
Lead sponsor
Oncovision Inc
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 31, 2026, 9:36 PM EDT
Completed Phase 1 Interventional

Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer

NCT03696771
View directory record Official record
Conditions
NON-breast HER2+ Malignancies
Interventions
NJH395
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 31, 2026, 9:36 PM EDT